Form 4: Skye Bioscience CFO Sells Shares to Cover Tax Obligations

Skye Bioscience's Chief Financial Officer, Kaitlyn Arsenault, sold a total of 43,396 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Summary

• Kaitlyn Arsenault, the Chief Financial Officer of Skye Bioscience, Inc., sold shares of the company's common stock.
• The sales were executed on November 15, 2024, and November 18, 2024.
• A total of 190 shares were sold on November 15 at a price of $5.55 per share.
• On November 18, 43,206 shares were sold at a weighted average price of $4.99 per share, with individual transactions ranging from $4.98 to $5.08.
• These sales were to cover tax withholding obligations associated with the vesting of performance-based restricted stock units.
• Following these transactions, Ms. Arsenault beneficially owns 166,342 shares of Skye Bioscience common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not a reflection of the company's performance or future prospects. The sentiment is neutral.

Management Comments

• The sales were to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary transactions by the Reporting Person.

Industry Context

Insider sales are a common occurrence, especially when executives receive stock-based compensation. These transactions are often related to tax obligations and are not necessarily indicative of a negative outlook on the company's future.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, but are not expected to significantly affect shareholders.
• The transactions do not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Skye Bioscience, insider trading, stock sale, CFO, Kaitlyn Arsenault, tax obligations, restricted stock units, share sale